On June 30, 2024, the "China ESG (Corporate Social Responsibility) Release" event, jointly organized by the CCTV Finance Program Center, the State-owned Assets Supervision and Administration Commission of the State Council, the All-China Federation of Industry and Commerce, and the Economic Research Think Tank of the Chinese Academy of Social Sciences, was successfully held in Beijing. The "China ESG Listed Companies Pioneer 100" list was officially released during the event. Sino Biopharm stood out from 972 companies for its continuous, high-quality ESG management and outstanding performance, and was selected for the second consecutive year.

The "China ESG Listed Companies Pioneer 100 (2024)" list used a sample space of 6,471 Chinese listed companies from both A-shares and H-shares. Based on factors such as market capitalization, ESG report publication status, listed company influence, and ESG activity, 972 listed companies were comprehensively selected as evaluation subjects. Ultimately, the 100 listed companies with leading ESG evaluation results were selected for the 2024 "Pioneer 100" list. Being selected for this list for two consecutive years represents the continued affirmation of Sino Biopharm's ESG governance and practices by relevant authoritative institutions.

In 2023, under the guidance of its "CARE"-centric ESG strategy, Sino Biopharm continued to promote key ESG initiatives such as low-carbon transformation, responsible supply chain construction, and employee growth, practicing responsible corporate operations through high-quality ESG practices.

In terms of low-carbon transformation, the Group was the first in the industry to initiate carbon neutrality pathway planning and actively promoted special projects for energy conservation and emission reduction, resulting in a steady year-on-year decrease in carbon dioxide emission intensity. At the supply chain management level, the Group successively completed key tasks such as establishing a supplier ESG management team, formulating the "Supplier Code of Conduct", and disseminating it to all core suppliers. In terms of employee growth, the Group released the "Human Resources Development Strategy", with the talent pipeline being upgraded annually and employee satisfaction continuously improving.

Being selected for CCTV's "China ESG Listed Companies Pioneer 100" list for two consecutive years represents the full affirmation of Sino Biopharm's ESG management work and performance in recent years by domestic authoritative institutions and media. In the future, Sino Biopharm will persist in practicing the Group's mission of "improving the quality and protecting the dignity of human life" through high-quality ESG management, seek health and well-being for more patients, and contribute to the sustainable development of the industry and even the nation.